Clinical and Biochemical Markers for Prediction of Preeclampsia

Jašović-Siveska, Emilija

doi:10.15406/ogij.2017.06.00198

Cited by 1 publication

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The changes in the values of the biochemical markers are described as a manifestation of impaired placentation due to inadequate trophoblastic invasion of the spiral arteries 2,32 . PlGF and PAPP‐A have shown promising results in early prediction of preeclampsia, preterm delivery, FGR and aneuploidies 33,34 . They have been studied as individual markers, where it has been obtained for PlGF a prediction of 53.5% with 5% of false positive for early onset of preeclampsia; and for PAPP‐A the prediction described was 10–20% 33 .…”

Section: Discussionmentioning

confidence: 99%

“…2,32 PlGF and PAPP-A have shown promising results in early prediction of preeclampsia, preterm delivery, FGR and aneuploidies. 33,34 They have been studied as individual markers, where it has been obtained for PlGF a prediction of 53.5% with 5% of false positive for early onset of preeclampsia; and for PAPP-A the prediction described was 10-20%. 33 Even though these biochemical markers are not considered to be good enough for being used alone, they have shown better results as a part of combined screening, by giving a higher prediction and reducing the false positive rates.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of preeclampsia and fetal growth restriction screenings at first trimester in a high‐risk population

Infante

Uriel

Porras-Ramírez

et al. 2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: To compare the sensitivity and specificity of screening for preeclampsia and FGR including maternal characteristics, mean arterial blood pressure and uterine artery pulsatility index and the combined screening, which adds biochemical markers, such as placental growth factor (PlGF) and pregnancy-associated plasma protein-A (PAPP-A), in a sample of high risk population for hypertensive disorders. Methods: This is a prospective study with 527 singleton pregnancies at 11-14 weeks of gestation. Maternal characteristics, biochemical and biophysical markers were studied to determine the development of preeclampsia and FGR by using receiver operating characteristic curves. Results: For preeclampsia, screening, including sociodemographic data plus biophysical markers, had a sensitivity and specificity of 70.3% (CI% 64.3-75.2) and 93.8% (CI% 90.9-96.8), respectively. Combined screening, which includes sociodemographic data, biophysical (mean blood pressure and uterine artery pulsatility index) and biochemical markers (PlGF and PAPP-A), increased sensitivity and specificity up to 85.5% (CI% 80.2-90.3) and 96.3% (CI% 91.4-98.9), respectively. For FGR, sociodemographic data plus biophysical markers had a sensitivity and specificity of 57.8% (CI% 50.1-63.4) and 80.1% (CI% 74.3-85.9), respectively. Combined screening increased sensitivity and specificity up to 67.2% (CI% 52.1-71.3) and 82.7% (CI% 75.2-90.1), respectively. Conclusion: Combined screening for preeclampsia and FGR at 11 to 14 weeks of gestation, which includes maternal characteristics, mean blood pressure, uterine artery pulsatility index, PAPP-A and PlGF, has higher sensitivity and specificity than other screening options. Therefore, considering all these variables during screening is recommended for a superior opportunity of identifying pregnant women in risk for preeclampsia and FGR, especially in a high-risk population.

show abstract

Section: Discussionmentioning

confidence: 99%